This site is intended for healthcare professionals only

MenB vaccine could be added to childhood vaccinations

Written by: | Published:

MenB vaccine could be added to childhood vaccinati MenB vaccine could be added to childhood vaccinations

The Department of Health (DH) has stated its intent to introduce the meningitis B vaccine into the childhood vaccination programme.

The Joint Committee on Vaccination and Immunisation (JCVI) advised that evidence shows the Bexsero® vaccine, developed by Novartis, is effective in preventing MenB in infants and should be included in the childhood vaccination programme, subject to it being made available by the manufacturer at a cost-effective price.

The JCVI recommended adding the vaccination to the primary childhood programme, meaning that infants will be immunised from two months of age.

Barbara Stuttle, the chair of the Association for Nurse Prescribers, said that this was a pioneering step. 'This will save lives and prevent some children living with complications from the disease. The important thing for nurses is that they understand the components of the vaccine they are giving and, importantly, side effects and contra-indications. Nurses are very experienced in dealing with new drugs and what they have to do and know before giving any medication to patients ensuring it is safe.'

Deputy chief medical officer professor John Watson said: '[The DH] will be working closely with Novartis and if negotiations are successful, we hope to work with the other UK health departments to introduce the vaccine as quickly as possible.'

Meningitis charities have been campaigning for the use of the vaccination since last year when it was limited due to high costs.

Professor Andrew Pollard, chairman of the JCVI and professor of paediatric infection and immunity at the University of Oxford, said: 'After very careful consideration, JCVI concluded that use of the new vaccine would reduce cases of meningococcal meningitis and septicaemia, and lead to a reduction in deaths, limb amputations and brain injury caused by the disease. The JCVI has published its recommendation to the UK health departments that if the new vaccine can be purchased at a low price, it should be used in the routine immunisation programme for babies in the UK to prevent disease.'

The JCVI also advised the vaccine be offered to three and four month-olds as a one-off catch-up programme when it is introduced.

What do you think? Leave a comment below or tweet your views to @IndyNurseMag

This material is protected by MA Healthcare Ltd copyright.
See Terms and Conditions.



Please view our Terms and Conditions before leaving a comment.

Change the CAPTCHA codeSpeak the CAPTCHA code

Read a free issue from Practice Nursing

Register to read a free issue from our sister publication, Practice Nursing.

Including articles on asthma, diabetes and more. Read your copy.


Sign up to the newsletter


Independent Nurse is the professional resource for primary care and community nurses, providing clinical articles for practice nurses and prescribers.


Subscribe to our newsletter and stay up to date with the latest nursing news.

Stay Connected

Stay social with Independent Nurse by following us on Twitter, liking us on Facebook or connecting on LinkedIn.


Need access to some of our older articles? You can view our archive, or alternatively contact us.

Contact Us

MA Healthcare Ltd.
St Jude's Church, Dulwich Road
London, SE24 0PB

Tel: +44 (0)20 7738 5454
Registered in England and Wales No. 01878373

Meet the team


Find out how to contribute to Independent Nurse here.